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ABSTRACT 
 
Membrane proteins interact intimately with the lipid bilayer in which they are embedded. 
Interactions between membrane proteins and ligands such as lipids and other small molecules 
can affect protein structure and function. Ion mobility-mass spectrometry (IM-MS) has recently 
emerged as a valuable tool for interrogating the interactions between protein and individual 
ligands, offering direct measurements such as stoichiometry, molar intensities and gas-phase 
mobility for each ligand-bound state of a protein complex. This technique is applied to examine 
the effect of direct ligand binding on model membrane proteins, such as the ammonium channel 
(AmtB) from e.coli and mammalian inwardly rectifying potassium channels (Kir) expressed in 
Pichia yeast. Studies presented here focus on the isolation of direct protein-ligand interactions 
from ensemble measurements using the model AmtB-lipid complexes, methodologies on 
mammalian protein preparation for high-resolution native mass spectometry, and the discovery 
of selectivity of a Kir channel towards the toxin peptide Tertiapin Q (TPNQ) and phosphorylated 
phosphotidylinositdes (PIPS), an essential signaling lipid required for Kir channel function. 
Stabilization parameters calculated from isolated AmtB-lipid complexes were compared to 
ensemble mass measurements to provide insight on the interactions between AmtB and 
phospholipids, and also provides a basis for methods used for the more complex Kir channels. 
After optimizing expression and purification methods for the mammalian Kir3.2 (GIRK2) 
channels for native mass spectrometry, the first high-resolution measurements for GIRK2-lipid 
complexes and TPNQ binding effects were analyzed. New data revealed that the closed and open 
states of the channel, as mimicked by a mutant R201A, can tune GIRK2’s PIP selectivity such 
that the open form prefers the PIP isoforms known to activate the channel.  
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NOMENCLATURE 
 
MS Mass Spectrometry 
IM Ion Mobility  
AmtB Ammonium Channel (from e.coli) 
GIRK2 G-protein Activated Inwardly Rectifying Potassium Channel 3.2 / Kir3.2  
CIU Collision Induced Unfolding 
ATD Arrival Time Distribution 
DDM n-Dodecyl-β-D-Maltopyranoside 
C8E4 Tetraethylene glycol monooctyl ether 
C10E5 Pentaethylene glycol monodecyl ether 
PIP Phosphorylated Phosphatidylinositides 
Top-Down MS Mass spectral analysis where the protein is intact 
Bottom-Up MS Mass spectral analysis where the protein is digested and then fragmented 
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  CHAPTER I 
 INTRODUCTION TO NATIVE ION MOBILITY MASS SPECTROMETRY (IM-MS) 
 
 Membrane proteins interact intimately with the lipid bilayer in which they are embedded 
[1]. Many vital cellular processes rely on membrane proteins and their function, including 
trafficking and signal transduction [2-4]. Analyses in the past decade show that over half of all 
drugs on the market target integral membrane proteins [5, 6]. Detailed understanding of how 
lipids affect the structure and function of proteins is therefore important for understanding 
fundamental biological processes and diseases. Recently, mass spectrometry (MS) approaches 
have emerged that can quantify individual binding events of protein-ligand complexes, and when 
performed in unison with an ion mobility device, ions are separated based on their shape and 
charge. This method, referred to as Ion mobility mass spectrometry (IM-MS), provides insight 
into protein conformation by reporting on the rotationally averaged collision cross section [7, 8]. 
 
Nano electrospray ionization is routinely employed to introduce intact protein complexes 
into a mass spectrometer that is tuned to maximize desolvation – the liberation of protein 
complexes from solvent droplets – and minimize activation of the ions to retain solution-state 
structures [9, 10]. Depending on the instrument, desolvation, including activation, can be 
accomplished, for example, through adjusting source pressure, source temperature, and 
increasing the potential on specific elements, such as “cone” voltage (a number of review articles 
discuss this in further detail [11-14]). More specifically, increasing source temperature, for 
example using a heated-capillary, can effectively desolvate ions through “in-source” collisional 
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activation, however elevated temperatures can lead to dissociation of noncovalent soluble protein 
complexes [15-20]. 
 
Mass spectra of membrane protein complexes recorded under instrument settings 
typically used for soluble proteins often result in a large, unresolved hump [9, 21, 22]. Thus, 
membrane proteins require a larger degree of activation, which is typically achieved in the trap 
or collision cell of the instrument, in order to desolvate, liberate them from the detergent 
micelles, and yield resolved mass spectra [9, 21, 23-25]. Although membrane proteins require 
more activation compared to their soluble counterparts, the excess detergent and lipid form a 
protective layer that protects them during activation such that native-like conformations can be 
observed by ion mobility post-detergent removal [21, 26-28]. Minimal increases in energy 
(above the threshold to strip detergent from the membrane protein complex) can perturb 
membrane protein structure, similarly to soluble proteins [27]. 
  
IM-MS is well suited for recording collision-induced unfolding (CIU) profiles of ions by 
measuring their mobility post collisions with neutral gas molecules in the trap, which can 
provide useful information for molecular analysis [29, 30] Such methods have been used to 
describe conformation and stability of large protein complexes and how events such as ligand 
binding can affect their structure [9, 30-33]. Unlike other biophysical approaches, where 
typically the observable is the ensemble of species (apo protein and ligand-bound states) in 
solution, IM-MS is capable of resolving individual protein-ligand binding events and 
characterizing their structural and conformational effects. For example, one study distinguished 
the class of ligand bound to a protein kinase, a soluble protein, by their CIU profiles [34]. Of 
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late, CIU-based quantitative IM-MS methods have been developed to determine how lipid-
binding events stabilize membrane protein complexes [27, 35]. Using the software program 
Pulsar [35], we can easily generate CIU profiles for apo and lipid bound states and use 
algorithms to quantify the transitions in the unfolding pathway. The stability afforded by the 
bound lipid is calculated by the sum of the differences between transitions in the CIU profiles for 
apo and lipid bound states. This IM-MS method used in earlier works demonstrated that different 
lipids can stabilize membrane proteins to varying degrees, with the most stabilizing lipids 
modulating the structure and function of membrane proteins [27]. As an example, a previous 
study have shown that the activity of the bacterial water channel aquaporin Z can be modulated 
nearly three-fold by the binding of cardiolipin, a lipid that significantly stabilized the channel in 
IM-MS studies. However, the molecular mechanism behind the increased activity remains 
unclear. More details on how this technique interrogate protein complexes, especially membrane 
proteins, will be helpful for studying more challenging systems, such as eukaryotic membrane 
complexes.  
 
CIU profiles of membrane proteins are typically performed on the entire ensemble (apo 
and lipid bound species) that raises uncertainty to the contribution of individual lipids and the 
species that are ejected in the unfolding process. During the CIU process, where collision voltage 
is increased in a stepwise fashion, the bound ligand(s) may eject from the complex as neutral or 
charged species. If the ligand ejects as a neutral, the signal from remaining charged species will 
contribute to the signal minus the mass of the ejected ligand, giving rise to heterogeneity of 
distinct apo and ligand bound states. In contrast, a ligand ejected as charged species could alter 
the initial charge state of the ion, such as for collisionally activated dissociation of ribonucleases 
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in complex with nucleotides [36], and the signal for charge-stripped ion would contribute to 
neighboring ion(s). As current CIU methods for membrane proteins do not isolate ions prior to 
collisional activation, the CIU profile for a given apo or lipid bound state can be compromised 
by overlapping ions that are the product of the protein complex minus lipid(s) ejected as either 
neutral or charged species. Our studies mainly focuses on the further development of existing 
IM-MS methods to probe membrane protein lipid interactions. We employed mass spectrometry 
ion mobility mass spectrometry (MS-IM-MS), which has been shown to allow for greater depth 
of information [37, 38]. In this dissertation, two membrane protein systems will explored. The 
first being the ammonia channel (AmtB) from Escherichia coli as a model membrane system for 
establishing the methodology, and the second being a mammalian inwardly rectifying potassium 
channel for further biophysical details on ligand interaction and selectivity.  
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CHAPTER II* 
NATIVE IM-MS STUDY OF AMTB 
 
 We selected the trimeric ammonia channel (AmtB) from Escherichia coli as the model 
integral membrane protein to bind to select phospholipids, some of which details have been 
described in other studies [9, 27, 39]. In the Synapt G1 instrument [40] the quadrupole is located 
before the collision cell, where collisional activation is typically applied to membrane proteins 
[27], making it a necessity to have a resolved mass spectrum prior to entering the quadrupole in 
order to isolate specific ions. In this study, we investigated higher source temperatures as a 
source of “in-source” collisional activation to release membrane proteins lipid complexes from 
the detergent micelle. By this method, we could record resolved mass spectra prior to entrance 
into the quadrupole and for the first time isolate ions of AmtB-lipid complexes in the quadrupole. 
After successfully isolating specific lipid-bound states of AmtB, we generated CIU profiles by 
collisional activation in the collision cell, which is located after the quadrupole. These CIU 
profiles are free of ensemble effects, such as contributions from product ions that have ejected 
lipid(s). We then compare results from IM-MS and MS-IM-MS approaches to provide insight 
into how CIU profiles can be affected by lipid ejection and the relationship to measured 
biophysical parameters. 
  
                                                 
*Reprinted with permission from “Characterization of Membrane Protein–Lipid Interactions by 
Mass Spectrometry Ion Mobility Mass Spectrometry” by Liu et al., 2016, J Am Soc Mass Spect. 
28, 579-586, Copyright 2016 by Spring Nature 
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Methods in Studying the Prokaryotic Channel AmtB 
 
Protein expression and purification 
The ammonia channel (AmtB) was expressed and purified from Escherichia coli. AmtB 
(residues 26-428) gene was amplified by polymerase chain reaction (PCR) with Q5 high-fidelity 
DNA polymerase (New England Biolabs). pET15b vector (Novagen) was linearized by XhoI 
(New England Biolabs) and gel purified (QIAquick Gel Extraction Kit, Qiagen), and used in an 
In-Fusion cloning reactions (Clonetech) to generate a TEV protease cleavable C-terminal fusion 
to maltose binding protein preceded by a secretion signal peptide (pelB) and 6x His-tag sub-
cloned from Hilf et al.[41].  The resulting vector was linearized with NdeI and NheI (New 
England Biolabs), gel purified and used in subsequent In-Fusion cloning reactions along with 
AmtB PCR products and primers designed for an In-Fusion cloning reaction to generate AmtB-
MBP expression plasmids. The plasmid was transformed into E. coli BL21 (DE3) ArcticExpress 
(Agilent) competent cells. Colonies grown on selection plates were inoculated into 50 mL Luria 
Broth (LB) and grown overnight at 37 °C, One liter Terrific Broth (TB) in 2 liter shaker flasks 
were inoculated with 4 ml of overnight culture and grown at 30 °C until the culture reached 
OD600nm between 0.6 to 0.8. Flasks with culture were chilled in an ice water bath for 10 minutes 
for cold-shock, and Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the culture at a 
final concentration of 0.5 mM. The culture is then grown overnight at 30 °C before cells were 
collected. Cell pellets were formed by centrifugation at 5,000g for 10 min at 4 °C, and then 
resuspended in Tris-buffered saline (TBS), pelleted by centrifugation at 5,000g for 10 min at 
4 °C and stored at −80 °C. Cell pellets were thawed and resuspended at 20 mL per litre of culture 
in buffer A (300 mM sodium chloride, and 20 mM 2-amino-2-hydroxymethyl-propane-1,3-diol 
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(Tris), pH 7.4 at room temperature) supplemented with a complete protease inhibitor tablet 
(Roche). The cell suspension was passed 3 times through an M-110 microfluidizer 
(Microfluidics) at 20,000 psi. Insoluble material was pelleted by centrifugation at 20,000g for 25 
minutes at 4 °C. The supernatant from the lysate was centrifuged again at 115,000g for 2 hours at 
4 °C to pellet the membranes. Membrane pellets were resuspended in ice-cold buffer B (150 mM 
sodium chloride, 20% glycerol, 5 mM BME and 20 mM Tris, pH 7.4 at room temperature), 
homogenized using a Dounce tissue grinder (Wheaton Glass). AmtB-MBP was extracted from 
homogenized membranes in buffer B supplemented with 2.5% DDM (n-Dodecyl-β-D-
Maltopyranoside, Anatrace) overnight at 4 °C on a rotating mixer set to gentle speeds. Extracted 
membrane proteins were clarified by centrifugation at 40,000g for 25 min at 4 °C, and the 
supernatant was filtered before loading onto a 5 mL HisTrap-HP column (GE Healthcare) 
equilibrated in buffer C (150 mM sodium chloride, 10% glycerol, 20 mM imidazole, 0.025% 
DDM and 50 mM Tris, pH 7.4 at room temperature). After the clarified supernatant was loaded, 
the column was initially washed with 20-30 mL of buffer C supplemented with an additional 
0.5% of DDM, and the membrane proteins were exchanged into buffer E until a steady baseline 
for UV absorbance at 280 nm was achieved. AmtB-MBP were eluted with a linear gradient from 
10% to 100% buffer D (100 mM sodium chloride, 10% glycerol, 500 mM imidazole, 0.025% 
DDM and 50 mM Tris, pH 7.4 at room temperature) over 15 mL, and peak fractions were 
pooled. The fusion protein solution was loaded through a 26/10 desalting column desalting (GE 
Healthcare) equilibrated in buffer C to remove excess imidazole, and peak fractions were once 
again pooled. The fusion protein is then supplemented with 5mM bME (β-mercaptoethanol) and 
his-tagged TEV protease and allowed to incubate overnight at 4 °C. The solution was then 
filtered and passed through a 5mL HisTrap-HP column again equilibrated in buffer C, with flow-
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through containing the untagged AmtB protein which is collected and concentrated using a 
100kDa molecular weight cut off filter. Notably, the AmtB protein with its C-terminal tags 
removed contained the additional protein sequence ASGENLYFQ, resulting from the TEV 
protease recognition sequence and cloning restriction site. Concentrated protein was either used 
immediately or flash-frozen in liquid nitrogen and stored at -80 °C.  
 
Sample preparation for native mass spectrometry  
Flash-frozen AmtB samples thawed on ice or freshly prepared samples were detergent 
exchanged by size exclusion chromatography (SEC). Membrane protein samples were injected 
onto a superdex 200 GL 10/200 SEC column (GE Healthcare) equilibrated in buffer E (150 mM 
sodium chloride, 10% glycerol and 50 mM Tris, 0.5% tetraethylene glycol monooctyl ether, 
pH 7.4 at room temperature). Peak fractions containing the detergent-exchanged AmtB protein 
were collected and concentrated using a 50 kDa molecular weight cut off filter, and is either used 
directly or flash-frozen in liquid nitrogen and stored at -80 °C. It is important to note that C8E4, 
or tetraethylene glycol monooctyl ether, act as a cryoprotectant along with the glycerol in buffer 
E, and there are no observable differences in mass spectra quality after freeze-thaw of a well-
purified AmtB sample. The protein is buffer exchanged into mass spectrometry buffer AA, or 
200 mM ammonium acetate containing 0.05% C8E4, pH 7.5 (by ammonium hydroxide) using a 
centrifugal buffer exchange device (Micro Bio-Spin 6 columns, Bio-Rad).  
 
Stock solutions of synthetic phospholipids with 16:0-18:1 acyl chains (Avanti Polar 
Lipids Inc., Alabama, USA) were purchased dissolved in chloroform. Hamilton syringes were 
used to aliquot the appropriate amount of chloroform solution into a glass vial, and a lipid film 
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was made by applying a constant stream of nitrogen gas. The lipid aliquot was further dried 
inside a desiccation chamber overnight, and then dissolved in AA buffer supplemented with 
0.5% C8E4 and 5 mM 2-mercaptoethanol (β-ME). 4 uL of AmtB protein solution (at 80 nM) 
was mixed with 4 uL of lipid solution (at 8 uM) to form a AmtB-lipid complex, incubated at 
room temperature for 2 minutes, and the mixture is back filled into a gold-coated glass emitter. 
The glass emitters were made by pulling glass capillaries (Sutter Instrument) using a Sutter P-97 
micropipeete puller, and gold-coated with a Leica EM ACE600 sputter coater.  
 
Protein and Lipid Quantification 
Protein concentration was determined with the DC Protein Assay kit (Bio-Rad) using 
bovine serum albumin as the standard. Phospholipid concentration was determined by 
phosphorous analysis [42, 43].  
  
Ion Mobility-Mass Spectrometry (IM-MS) 
IM-MS and MS-IM-MS were performed on a Synapt G1 HDMS instrument (Waters 
Corporation) equipped with a radio frequency generator to isolate higher m/z species (up to 32k) 
in the quadrupole, and a temperature-controlled chamber attached to the source region and 
sample inlet in order to minimize changes in solution temperature due to changing instrument 
settings in the source region as well as atmospheric disturbances. Instrument parameters were 
tuned to maximize signal intensity for IM-MS and MS-IM-MS while preserving the native-like 
state of AmtB. The source temperature was set to 23 (ambient), 40, 80, or 120 ºC, capillary 
voltage of 1.7kV, sampling cone voltage of 200V, extractor cone voltage of 10V, argon flow rate 
in the trap was set to 7 mL/min (5.2 x 10-2 mbar), and transfer collision energy at 15V. The T-
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wave settings were for trap (300 ms-1/1.0V), IMS (300 ms-1/20V) and transfer (100 ms-1/10V), 
and trap DC bias (35V). CIU was performed from 10V to 200V on trap collision energy in 10V 
steps. For MS-IM-MS, the quadrupole LM resolution was set to 6. To minimize differences 
caused by variations in gold-coated glass capillary tips, each replicate was collected from one tip 
using the same preparation of protein-lipid mixture. 
 
Data Processing and Analysis 
IM-MS and MS-IM-MS data were processed with the software program Pulsar [35]. The 
intensities of protein and protein-lipid species were deconvoluted and converted to mole fraction 
using UniDec [44].  
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Results and Discussion 
 
Activation of membrane protein complexes for MS-IM-MS 
As a step towards MS-IM-MS of membrane protein complexes, we set out to develop 
methods to activate membrane proteins in the source region such that resolved ions can 
confidently be isolated in the quadrupole prior to entering the collision cell. Starting with a 
modest trap collision voltage setting of 20V and a maximum setting for the cone voltage (200V), 
the mass spectrum we obtained at ambient source temperature (23 °C) was poorly resolved and 
not ideal for isolating apo and lipid bound states of AmtB (Fig 1). To further activate ions 
upstream in the instrument, we then explored raising the source temperature from ambient to 40, 
80, and 120 °C. With increasing source temperatures we observed an overall increase in signals 
for resolved AmtB species, especially for the lower charge states of the protein complex (Fig 1). 
It is unclear why there is an increase in abundance of lower charge states at elevated source 
temperatures, but plausible explanations could be charge stripping in the source region, or 
improved desolvation for lower charge state ions in the instrument. Interestingly, increasing 
source temperature under modest trap settings resulted in resolved mass spectra comparable to 
that collected at ambient source temperature with 60V applied to the collision cell. Thus, 
elevated source temperature can provide sufficient “in-source” collisional activation to liberate 
AmtB from the detergent micelle.  
 
CIU profiles acquired by IM-MS and MS-IM-MS 
We then carried out a series of experiments at different source temperatures to understand 
the impact of elevated source temperature on CIU of AmtB bound to lipids (Fig 2). Herein we 
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focus on the 15+ charge state of AmtB bound to lipid(s) since their CIU profiles have been 
previously characterized and peer-reviewed [27]. The first transition from a native-like state, 
where the measured collision cross section (CCS) agrees with the calculated CCS for AmtB [27], 
decreases roughly by 20V with each 40 °C increase in source temperature (Fig 2a). A similar 
drop in collision voltage for the two subsequent transitions was observed as well. We speculate 
that the change in the collision voltage required to unfold the AmtB-lipid complexes to be the 
result of an overall increase in internal energy. This would be consistent with reports for soluble 
system, where increased “in-source” activation raises the internal energy of ions and lowers the 
collisional activation post-source to fragment or dissociate noncovalent complexes [17, 45].  
Moreover, we also observed an increase in the width of the arrival time distribution (ATD) for 
all species with increasing source temperature and the native-like ATD nearly doubling in width. 
The cause behind this interesting observation is unclear, but one plausible explanation is that 
there are contributions from other ions that have either ejected bound lipids or charge-stripped in 
the collision cell.  
 
Given our ability to isolate ions of AmtB-lipid complexes, we recorded CIU profiles of 
AmtB bound to two lipids by collisional activation in the collision cell, which is located after the 
quadrupole (Fig 2b). After isolating the ions corresponding to the 15+ charge state of AmtB 
bound to two 1-palmitoyl-2-oleoyl (PO) phosphatidic acid (POPA) lipids, we subjected these 
ions to increasing trap collision voltage to record MS-IM-MS CIU profiles. In contrast to IM-MS 
CIU profiles, the unfolding transitions occurred at significantly lower trap collision voltage. For 
example, at a source temperature of 40 °C the first transition was at 75V versus 130V for IM-MS 
and MS-IM-MS, respectively. In addition, the drop in transition collision voltage with increasing 
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source temperature was roughly 7V, approximately a third of the value observed in IM-MS. Last 
but not least, the width of the ATD was consistent among the source temperatures tested,  
implying that source temperature is not responsible for ATD widening observed in IM-MS. Most 
interestingly, we noted a faint transition occurring around ~75V that coincidentally matched the 
first transition observed in the MS-IM-MS CIU profile (Fig 2a-b, left panels). Upon closer 
examination, it appears there is an apo MS-IM-MS CIU profile that faintly underlies the profile 
acquired by IM-MS, specifically weak ATD distributions starting to appear at 8 and 10 
milliseconds and from collision voltages indicated by arrows. Taken together, our results provide 
evidence that IM-MS CIU profiles of protein-lipid complexes can be heterogeneous, which we 
hypothesize is due to the contribution from product ions after ejection of their bound lipid(s). 
 
Ejection of bound lipid(s) from AmtB during CIU 
To understand how bound lipids eject from AmtB, we first examined the mass spectra in 
IM-MS CIU profiles. In general, we observed a gradual decrease in signals corresponding to 
AmtB bound to lipid with increased collision voltage (Fig 3a). We then investigated mass spectra 
in MS-IM-MS CIU profiles. The signal for the isolated 15+ charge state of AmtB bound to two 
lipids was absent at a trap collision voltage above 160V (Fig 3b), which is dramatically different 
from IM-MS profiles where lipids remained present even above collision voltage settings of 
200V (Fig 3a, Fig 5). After examining mass spectra for MS-IM-MS profiles of AmtB bound to 
two PO phosphatidylglycerol (POPG) molecules, we observed that even though AmtB(POPG)2 
gradually lost both bound lipids with increased trap collision voltage, the charge state of AmtB 
remained the same (Figure 3b), indicating that the bound lipids ejected as neutral (without 
charge) species. Interestingly, we could obtain a CIU profile for the product of AmtB(POPG)2 
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minus one POPG, yielding AmtB(POPG)1 (Fig 4a). Analysis of MS-IM-MS CIU profiles for 
AmtB bound to other lipids gave similar results, even when selecting ions corresponding to 
AmtB bound to one lipid (Fig 4b). Notably, all lipids investigated in this study ejected from 
AmtB as neutral species. Thus, the product ions after ejection of their bound lipid(s) in the CIU 
process compromise other ions of the same charge state but lower in mass i.e. mass minus the 
ejected lipid(s). 
 
To gain further insight into the lipid ejection process during CIU, we plotted the mole 
fraction of AmtB species from IM-MS and MS-IM-MS CIU profiles (Fig 5). As seen by IM-MS 
CIU profiles, the PO-type lipids have similar trends but slightly differ in the initial transition 
point where lipids start to eject. In contrast, the mole fraction of bound tetra oleoyl (18:1) 
cardiolipin (TOCDL) is fairly constant, with a ~14% change in the fraction of apo AmtB across 
the CIU profile. We then plotted the mole fraction for AmtB species derived from MS-IM-MS 
CIU profiles for AmtB bound to one (1x) or two (2x) lipids (Fig 5b-c). Similar to IM-MS, all the 
PO-type lipids exhibited similar patterns. However, an initial lipid loss occurring early on in the 
CIU profile doesn’t appear in the mole fraction plot from IM-MS. TOCDL was virtually constant 
with some ejection at higher collision voltage settings and an absence of apo AmtB for MS-IM-
MS 2x. The discrepancy for TOCDL dissociation is intriguing, but similar observations have 
been observed for some soluble protein-ligand systems [12, 36]. In general, the rapid ejection of 
lipid in general appears to happen at collision voltages where the third and fourth partially 
unfolded intermediates begin to appear in the CIU profile. It is also worth noting that these mole 
fraction plots can be a useful reference for quantifying lipid binding on other instruments, such 
as the Orbitrap [46]. 
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IM-MS and MS-IM-MS derived stabilization of AmtB lipid binding 
After establishing that lipids are ejected from AmtB as neutral species, we set out to 
determine the stabilization afforded by AmtB binding one and two lipids using IM-MS and MS-
IM-MS CIU profiles (Fig 6). The calculated stabilization for AmtB binding one lipid determined 
from IM-MS and MS-IM-MS CIU profiles are similar with IM-MS giving slightly higher values. 
The stabilization values for 1x are statistically indistinguishable, which is in agreement with our 
recent report on the thermodynamics of these lipids binding AmtB [39]. There is slight deviation 
for the binding of two lipids, where stabilization for binding of two lipids is the greatest for IM-
MS CIU profiles. The products of lipid ejection contributing to CIU profiles can in part explain 
the increase in stability. More specifically, this effect could potentially be enhanced for some 
lipids that readily dissociate from AmtB, providing a rationale for the increase in stabilization for 
the second lipid-binding event in some cases. In support of this idea, POPG and POPE have the 
most pronounced increase in AmtB stabilization for the second lipid-binding event, and these 
lipids appear to dissociate more readily from AmtB (see Fig 5c). Furthermore, stabilization for 
AmtB binding TOCDL, a lipid that does not readily eject from the complex, is indistinguishable. 
In short, the effects of lipid ejection on CIU profiles are enhanced for lipids that readily 
dissociate, and IM-MS and MS-IM-MS yield similar ranking of lipids that stabilize AmtB. 
 
As we used the same lipids in our recent study [39], we set out to compare stabilization 
values to equilibrium dissociation constants (KD). We found no correlation between the 
stabilization values and KD. The discrepancy between these two values could be rationalized by 
the unfolded protein and unfolded protein-lipid (or protein-ligand) complex differing in energy 
landscape, making the stabilization energy not equal to the binding energy of a ligand [39].  
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Summary and Conclusions 
 
Lipids have essential roles in the folding, structure, and function of membrane proteins 
[1-3, 27, 47-49], and the development of new methods to elucidate how lipids exert their effects 
are of great biological importance. Here, we describe the application of “in-source” collisional 
activation of membrane protein complexes to produce resolved ions that can be isolated in the 
quadrupole of a Waters Synapt G1 instrument while preserving their native-like structure in the 
gas-phase. Using this method, we collected for the first time MS-IM-MS CIU profiles for a 
membrane protein in complex with lipid. This led to the finding that bound lipids eject from 
AmtB as neutrals, which gives rise to overlapping CIU profiles when using the IM-MS CIU 
method. This study have also shown that the stability for AmtB bound to different lipids do not 
vary significantly between IM-MS and MS-IM-MS measurements, and no correlation to 
biophysical parameters, such as KD, was found. This method to desolvate and isolate ions of 
membrane protein complexes will be advantageous for other MS methods, such as ultraviolet 
photodissociation [50] and surface induced dissociation [51, 52]. Most importantly, the robust 
technique and detailed understanding on the interpretation of IM-MS data will set the foundation 
on which more challenging protein systems can be studied. In the following chapter, a more 
complex mammalian potassium channel will be also subjected to a similar IM-MS method under 
native-like conditions.  
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CHAPTER III 
CHARACTERIATION OF MOUSE GIRK2 CHANNELS AND INTERACTIONS WITH 
SIGNALING LIPIDS AND TOXIN 
 
Introduction to GIRK2 Channels 
 
 With the establishment of robust native ion mobility mass spectrometry methods for 
quantitative measurements on membrane proteins, a more complex channel with well-established 
interactions with specific signaling lipids becomes an interesting candidate to interrogate. Inward 
rectifying potassium (IRK) channels are a family of membrane protein complexes that transport 
potassium ions across biological membranes into cells whereas outward flux is blocked by 
intracellular polyamines and magnesium [53, 54]. These channels are involved in numerous 
physiological processes, such as neuronal signaling, heart rate regulation and potassium 
homeostasis [54-56]. Mutations in IRK channels underlie a number of diseases including 
Andersen syndrome, Bartter syndrome and neonatal diabetes [57-59]. Activation of IRK and a 
number of other channels requires the signaling lipid phosphatidylinositol 4,5-bisphosphate 
(PI(4,5)P2), which represents a minor component of the cytoplasmic leaflet [60-68]. IRK 
channels are also regulated by a number of other molecules including anionic lipids, sodium, 
ethanol, and toxins [54, 69-76]. 
 
Atomic structures have revealed detailed interactions of PI(4,5)P2 with dioctanoyl (8:0-
8:0) acyl chains binding to chicken IRK2 (Kir2.2) and mouse G-protein gated IRK2 (GIRK2, 
Kir3.2) [64, 77, 78]. These structures reveal a similar fold with one PI(4,5)P2 bound per subunit 
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at the interface between the transmembrane domain (TMD) and cytoplasmic domain (CTD). The 
negatively charged, phosphate-rich head group of PI(4,5)P2 promotes coordination with lysine 
residues and backbone amides on GIRK2 [77]. PI(4,5)P2 binding to GIRK2 induces a slight 
rotation of the inner helix but insufficient to open the channel. An open, gated conformation is 
only achieved as a result of a four degree rotation of the CTD upon Gβγ binding between adjacent 
CTD subunits. The R201A mutation of GIRK2 (GIRK2R201A) does not require Gβγ binding to 
gate and the structure in complex with PI(4,5)P2 is in a gated conformation; However, there is an 
exaggerated rotation of the CTD compared to the gated wild-type channel. GIRK2R201A has been 
proposed to be a mimic of the Gβγ-protein activated state [77] and provides an opportunity to 
study the effect of the CTD orientation on PIP binding.  
 
In addition to PI(4,5)P2, electrophysiology studies have revealed the other six PIP 
isoforms can gate IRK subfamilies to various degrees [62, 68, 71, 79, 80]. For example, IRK1 
(Kir2.1) is activated primarily by PI(4,5)P2 but the channel appears to bind other PIPs with 
similar affinity [62, 80]. The hetero-tetrameric GIRK1/GIRK4 channel, which is in the same 
subfamily as GIRK2, can be activated with similar efficacy by PI(4,5)P2, PI(3,4)P2, PI(3,5)P2 
and PI(3,4,5)P3 [68]. ATP-sensitive potassium channels (KATP) are IRKs that are promiscuously 
activated by PIPs [62]. Moreover, GIRK1/GIRK4 has a strong dependence on the acyl chain 
chemistry of the PIP with the greatest activation for 18:0-20:4 tails [68], which is the most 
abundant form in mammalian cells [81]. In contrast, IRK1 does not display a preference towards 
the acyl chains of PIPs [68, 80]. Although functional assays report an overall pharmacological 
shift and not on the stoichiometry of bound PIPs, these studies demonstrate that IRKs are 
distinctly activated by PIP isoforms. In addition, anionic lipids, such as phosphatidylglycerol, not 
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only are required for gating of Kir2 channels but also increases sensitivity of Kir2 toward PIPs 
by ten to one-hundred fold [71, 82]. With these findings in mind, there is an emerging necessity 
for novel approaches to interrogate individual PIP binding events to these tetrameric ion 
channels in order to gain chemical insight into the impact of PIP isoforms and acyl chain 
chemistry on binding. 
 
Native mass spectrometry (MS) is a powerful biophysical technique for investigating 
membrane proteins and their interactions with small molecules, such as lipids [27, 32, 39, 83]. 
As mentioned in the previous chapter, native MS can interrogate individual ligand-binding 
events to protein complexes while preserving non-covalent interactions in the mass spectrometer 
[27, 84-87]. To expand on the importance of this point and to provide an example, native MS 
coupled with a temperature controlled source has been used to obtain thermodynamics for 
membrane protein interactions with lipids and protein [39, 88]. Notably, thermodynamic 
parameters for protein–ligand and protein-protein interactions determined using other 
biophysical techniques, such as isothermal titration calorimetry and surface plasmon resonance, 
are in agreement with those obtained using native MS [39, 88, 89]. Although an improperly 
tuned instrument could adversely affect the fraction of lipid bound to the protein [87], prior 
native MS studies [39, 88, 89] establish that a properly tuned instrument can measure 
equilibrium binding constants and thermodynamic parameters comparable to those measured in 
the solution phase. Moreover, MS has also revealed that specific protein-lipid interactions can 
stabilize protein complexes[27, 90] and allosterically modulate other interactions with protein 
[88], lipids [91], and drugs [83, 92]. This capability will be utilized in fundamental 
understanding of how channels such as GIRK can interact with its activator lipid, PIPs.  
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Although native MS has provided insight into a handful of membrane protein complexes, 
the rate-limiting step to obtaining a high-resolution mass spectrum – a prerequisite for detailed 
biophysical studies – is often frustrated by sample preparation and quality [9]. These challenges 
in general are exacerbated for eukaryotic membrane proteins, such as for G-protein coupled 
receptors, requiring considerable effort to optimize their purification [93]. Here, we optimized 
the purification of the mammalian GIRK2 channel for high-resolution native MS studies such 
that small molecules could readily be resolved. We then used native MS to study the binding of 
small molecules and PIP isoforms including different acyl chains to GIRK2 and the R201A 
mutant of GIRK2 that displays a rotation of the CTD similar to that when in complex with PIP 
and Gβγ [77].  
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Methods and Troubleshooting 
 
Construct preparation and expression of recombinant mouse GIRK2 in Pichia pastoris  
For construction of the GIRK2 expression plasmid, the KCNJ6 gene from Mus musculus 
(amino acid 52-380 used for structure determination [77]) was codon optimized for Pichia 
pastoris using the Codon Optimization Tool from Integrated DNA Technologies (IDT) and 
synthesized as a gBlocks gene fragment (IDT). The pPICZ vector to express chicken Kir2.2 was 
a generous gift from Dr. Roderick MacKinnon and subsequently modified to have terminal 
StrepII tag and 6xHis-tag for protein purification and eGFP to enable quantitation of 
recombinant protein expression. This vector was also modified to contain a TEV (Tobacco Etch 
Virus) protease site between the protein of interest and the purification/quantitation tags. In-
Fusion cloning kit (Clontech) was used to clone the codon optimized GIRK2 gene fragment into 
the modified pPICZ vector linearized with XhoI and EcoRI (New England BioLabs). This 
produced a construct which can express GIRK2-eGFP-StrepII-6xHis fusion protein under the 
control of the inducible alcohol oxidase promoter with eGFP used as a reporter of protein 
expression. The R201A mutant was generated using the QuikChange Lightning Site-Directed 
Mutagenesis Kit (Agilent) following manufacturer’s protocol. The resulting plasmids were 
verified by restriction digest analysis and DNA sequencing.  
 
The components of the recombinant protein could be arranged in ways such that either 
purification tag can be on the N- or C-terminus of the protein, or with both tags on one side in 
different orders. Several iterations of constructs were screened for both Kir2.2 and GIRK2, and a 
summary of the different expression efficiency and qualities by the different construct is as 
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follows. N-terminal StrepII tag causes the absence of protein expression while C-terminal 
StrepII-tagged recombinant protein can express properly, even though linker peptide and TEV 
sites separate the tag and the Kir/GIRK sequences. 6xHis tag does not interfere with expression 
on either N- or C-terminus. The resulting recombinant protein expressed, either from the N-
6xHis-Tev-GIRK2-TEV-eGFP-StrepII-C construct, or the N-GIRK2-TEV-eGFP-StrepII-6xHis-
C construct, expresses as a stable tetramer. The quality of the expressed recombinant protein 
from the two constructs seems comparable, but further validation by denatured, or top-down 
mass spectrometry would be necessary in order to accurately determine the sequence integrity of 
each monomer. Some work have been done to show that monomers of expressed recombinant kir 
channels can be phosphorylated multiple times, giving rise to heterogeneity in mass. Regardless, 
the N-GIRK2-TEV-eGFP-StrepII-6xHis-C was used in this study, and the pPICZ plasmid 
containing this construct was linearized with PmeI (New England BioLabs) before 
transformation into P. pastoris KM71.  
 
P. Pastoris strain and transformation comparison 
 Three strains tested for expression of GIRK2 were KM71, GS115 and SuperMan. Among 
them, KM71 and GS115 had moderate transformation efficiency by either electroporation or 
chemical transformation, while SuperMan showed markedly lower transformants. In addition, 
SuperMan transformants are observed as small, slowly dividing cells that tend to clump together 
when observed under a microscope, compared to the other two strains. The differences in the 
purified protein from different strains were not significant. The protein used in this study was 
purified from KM71 strain of transformants. It is necessary to empirically determine the optimal 
transformation method and growth conditions for generating well-expressing transformants.  
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Clonal selection and expansion 
Transformants were selected on YPD plates containing 0.6 M sorbitol, 500 to 1,000 
μg/mL zeocin and 2% agar. All the tested recombinant clones showed a methanol utilization plus 
or Mut+ phenotype. The P. pastoris integrant colony which showed highest eGFP level (i.e. 
greenest color) during small-scale expression screening (15 mL culture after 30 hours post 
induction with methanol) was used for large-scale expression. This step was closely monitored 
for possible bacterial contamination, which prevented adequate expression of protein. To 
minimize this, all media were supplemented with either kanamycin/ampicillin at 50 and 100 
ug/mL respectively, or penicillin/streptomycin mixture at 1:10 working concentration. To 
produce starter culture, a single colony of P. pastoris GS115/pPICZB-GIRK2-eGFP-StrepII-
6xHis was grown (27 °C, 220 rpm) for 20 hours in BMGY media (1.34% yeast nitrogen base, 
1% yeast extract, 2% peptone, 0.1 M potassium phosphate, pH 6.1, 1% glycerol, 0.4 μg/ml 
biotin, and 40 μg/mL histidine) containing 150 μg/mL zeocin. Cells were pelleted (1,500 g, 10 
min) and then resuspended in BMMY media (BMGY medium without glycerol but with 1% 
methanol) for induction with methanol. Harvesting cells may introduce unwanted bacterial 
contamination, so care should be taken here, including autoclaving centrifuge bottles, practicing 
sterile techniques, etc. Cultures were grown (27 °C, 220 rpm) for roughly 40 hours with addition 
of 0.5% methanol twice daily, with the first methanol addition to contain 0.1% polypropylene 
glycol 2000 as an anti-foaming agent (this seems to help maintain consistency in expression and 
microbe health). Longer expression time produces more protein, but can cause issues such as 
increased bacterial contamination, or the truncation of all expressed protein. Color, consistency, 
odor and cell shape must be checked before cells are to be harvested. Mixing contaminated cells 
or dying cells with healthy expression cells will cause unwanted heterogeneity in downstream 
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analysis that cannot be remedied. Specifically, cells should not have unpleasant odor, should be 
consistent in color, do not readily form clumps or settle when taken out of the shaker, and should 
be seen as turgid, consistently-sized oval spheroids under a conventional light microscope. Sick 
cells tend to be small and clump together, and some protease-deficient strains seems to have a 
tendency to look sick under the microscope. Ready-to-harvest cells were pelleted (1,500 g, 10 
min), resuspended in wash buffer (50 mM 2-amino-2hydroxymethyl-propane-1,3-diol [Tris], 150 
mM NaCl, pH 7.4), and then pelleted again. Cell pellets were stored at -80 ºC and typically used 
within 2 weeks. Longer storage time in the freezer causes quality issues, such as difficulty 
obtaining adequate amount of protein, or protein not binding to StrepTrap columns efficiently. 
 
Additional notes to protein expression in P. pastoris: the growth conditions and 
requirements for a particular clone, and/or type of protein expressed, can vary. Every material 
used throughout the culturing process must be examined for troubleshooting. As an example, 
yeast extract and casein peptone from certain vendors work well for all clones and strains, while 
other vendors only allow expression of certain clones and strains. 
 
Protein Expression and Purification  
Frozen P. pastoris pellets were thawed and resuspended in lysis buffer (300 mM KCl, 50 
mM Tris, pH 7.4 at room temperature) at a ratio of 1:4 cell weight to buffer volume ratio. The 
cell mixture was supplemented by a protease inhibitor cocktail tablet (Roche Pharmaceuticals) 
and was stirred until homogenized. The mixture was passed through an M-110PS microfluidizer 
(Microfluidics) at 30,000 psi for a total of four passes. Insoluble material was pelleted by 
centrifugation at 25,000 g for 30 min at 4 ºC. Supernatant was pooled and a final concentration 
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of 1.5% DDM (n-Dodecyl-β-D-Maltopyranoside, Anatrace) was applied to the mixture to extract 
membrane proteins while stirring at 4 ºC overnight. Imidazole was then added to final 
concentration of 10 mM, and the mixture was clarified by centrifugation (100,000 g, 10 ºC for 30 
min). The supernatant was then loaded onto an XK16/20 column (GE Healthcare) packed with 
15mL of Ni-NTA Agarose beads (Qiagen) pre-equilibrated by buffer A (150 mM KCl, 30 mM 
Tris, 10 mM imidazole, 10% glycerol and 0.025% DDM, pH 7.6 at room temperature). After the 
solution was passed through the column, 15 mL of wash buffer consisting of buffer A 
supplemented with an additional 0.5% DDM was applied. The column was then exchanged into 
several column volumes of buffer A or until a steady baseline for 280 nm absorbance was 
established. The protein was eluted with 40 mL of buffer B (150 mM KCl, 30 mM Tris, 300 mM 
imidazole, 10% glycerol and 0.022% DDM, pH 7.6 at room temperature). Peak fractions were 
pooled, then loaded onto a HiPrep 26/10 desalting column (GE Healthcare) pre-equilibrated with 
Buffer C (150 mM KCl, 30 mM Tris, 10 mM β-mercaptoethanol (BME), 10% Glycerol and 
0.022% DDM, pH 7.5 at room temperature). Peak fractions were pooled and then loaded onto 
two 5-mL StrepTrap HP Columns (GE Healthcare) connected in tandem pre-equilibrated in 
buffer C. Buffer D (150 mM KCl, 30 mM Tris, 10 mM BME, 4 mM d-desthiobiotin, 10% 
glycerol and 0.022% DDM, pH 7.5 at room temperature) was applied to elute recombinant 
protein from the StrepTrap HP Columns. Peak fractions were pooled and once again loaded onto 
a HiPrep 26/10 desalting column pre-equilibrated with Buffer C to remove d-desthiobiotin. This 
step is vital to the stability of the cleaved protein in subsequent purification steps. Peak fractions 
were pooled before adding His-tagged TEV protease produced in-house [94]. The mixture was 
incubated overnight at 9 ºC and then filtered through a 0.45 μm syringe filter (Pall Corporations). 
The protein solution was loaded onto a 5-mL HisTrap HP column (GE Healthcare) equilibrated 
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in buffer E (150 mM KCl, 30 mM Tris, 25 mM imidazole, 10% glycerol and 0.022% DDM, pH 
7.6 at room temperature). Flow-through containing the untagged GIRK2 was collected and 
concentrated using a 100,000 MWCO concentrator (Millipore) to roughly 2 mg/ml as determined 
by UV absorbance (with coefficient of 1 Abs = 1 mg/mL). The protein was flash-frozen in liquid 
nitrogen, stored at -80 ºC, and typically used within two weeks. These steps should consistently 
generate stable protein stock prior to the final polishing step for mass spectrometry analysis of 
GIRK2.   
 
GIRK2 Polishing for Native Mass Spectrometry Studies.  
About ~1 mg of purified GIRK2 protein solution was thawed and added to buffer F (150 
mM KCl, 50 mM NaCl, 30 mM Tris, 10 mM BME, 1 mM DTT [1,4-dithiothreitol], 10% 
glycerol, 15 mM DHPC [1,2-diheptanoyl-sn-glycero-3-phosphocholine] and 0.022% DDM, pH 
7.5 at room temperature). The ratio of protein solution to buffer F added is 1:8 by volume and the 
solutions were kept at 15 ºC before mixing. The mixture was immediately concentrated in a 
100,000 MWCO concentrator at 3,000 g and 15 ºC for 3 minutes, and the mixture was manually 
re-suspended with a pipette. This process was repeated until 1 mL of solution remain to avoid 
precipitation of the protein. 10 mL of buffer C was added to the concentrator and the sample 
slowly concentrated to a final volume of 500 L with repeated resuspension of the solution in the 
concentrator every 3 minutes to minimize aggregation. The mixture was then filtered through a 
0.22 μm spin-filter (Millipore) before being injected into a Superdex 200GL 10/300 (GE 
Healthcare) column equilibrated in buffer G (150 mM KCl, 50 mM NaCl, 30 mM Tris, 10% 
glycerol, 0.07% C10E5 (decylpentaglycol, Anatrace), and pH 7.4 at room temperature). Peak 
fractions containing delipidated GIRK2 were pooled and concentrated in a 100,000 MWCO 
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concentrator until 50 L total volume was reached. Concentrated proteins were either flash-
frozen in liquid nitrogen and stored at -80 ºC, or used directly by exchanging into MS buffer 
(100 mM ammonium formate, 0.065% C10E5, and pH 7.2 at room temperature) using a 
centrifugal buffer exchange device (MicroBio-Spin6, Bio-Rad) following manufacture’s 
protocol. Ammonium formate is used instead of the typical ammonium acetate due to GIRK2 
having slightly better shelf-life in this buffer. For convenience, the sample in MS buffer was 
aliquoted into 2 L fractions, flash-frozen in liquid nitrogen and stored at -80 ºC until used for 
experiments. During experiments, frozen aliquots of proteins were stored on dry ice until used 
for MS measurements. Notably, there should be very little observable difference in mass-spectral 
quality after a single freeze-thaw of GIRK2 proteins up until this point of this purification 
regime.  
 
Preparation of Phospholipids and Other Ligands for MS Binding Studies 
Phospholipid stock solutions were aliquoted. Chloroform was removed from the 
phospholipid ampoules, which were pre-aliquoted by Avanti Polar Lipid, by gentle nitrogen gas 
flow and then by desiccation overnight. For lipids purchased in powder form, chloroform was 
added, and the solution was transferred to a new glass vial and dried as described above. The 
dried lipid films were solubilized in the MS buffer with the exception of PIPs, where they were 
solubilized in water supplemented with 10mM bME. This is done to accommodate the making of 
multiple working stocks of PIPs in various buffers, and conserve material usage. Lipid 
concentrations were calculated directly from the weight of each aliquots in individual vials. The 
molar ratio of wild-type or R201A GIRK2 to phospholipids was held constant at a ratio of 1:6. 
Protein aliquots were kept at -80 ºC until immediately before usage, whereby they are mixed 
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with lipid solutions at a 1:1 volume ratio. Specifically, GIRK2 and lipid mixtures were held at a 
final concentration of about 500 nM and 3 μM, respectively. The R201A GIRK2 and lipid 
mixtures were at a final concentration of about 825 nM and 5 μM, respectively. These protein-
lipid mixtures were allowed to incubate for 1 minute at room temperature before loading into a 
gold-coated glass capillary tip produced in-house as previously described [27]. Briefly, 
borosilicate glass capillaries (Sutter Instruments BF150-86-10) were pulled into emitters with 
sharp tips by using the P1000 micropipette puller (Sutter Instruments), then subsequently coated 
with gold using a sputter coater (Leica EM ACE600). We have found that longer incubation time 
does not change the mole fractions of apo and lipid-bound proteins. These findings are in 
agreement with our previous studies on AmtB and lipid complexes [39]. 
 
Ivermectin (Alfa Aesar) was solubilized in DMSO and/or 100% ethanol, and dilutions 
made in MS buffer. No noticeable precipitation of ivermectin was observed after dilution in MS 
buffer until a final concentration of 2mM in 20% DMSO or 5% ethanol, 3% DMSO is reached. 
This sample was mixed with GIRK2 in a 1:5 ratio by volume of ivermectin to GIRK2. Tertiapin 
Q (TPNQ, Alomone Labs) was diluted directly in MS buffer to 100 μM or lower, and mixed 
with GIRK2 in a 1:1 ratio by volume.  
  
Native Mass Spectrometry (MS) and Data Analysis 
A Synapt G1 HDMS instrument (Waters Corporation) with a 32k RF generator was used 
for most of the data collected. Instrument parameters were tuned to maximize ion intensity and 
simultaneously preserve the native-like state of GIRK2. The capillary voltage was set to1.75 kV, 
sampling cone voltage at 200 V, extractor cone voltage at 10 V and argon flow rate at 7 mL/min 
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(5.2 x 10-2 mbar). The T-wave settings for trap (300 ms and 1/1.0 V), IMS (300 ms and 1/18 V) 
and transfer (100 ms and 1/10 V), source temperature (90 ºC) and trap bias (35 V) were also 
optimized. Trap and Transfer Collision Voltage were set to 100 V and 60 V, respectively, unless 
otherwise noted. Ion mobility mass spectrometry data were processed using the software 
program Pulsar [35] and de-convoluted using UniDec [95] followed by converting intensities of 
GIRK2 and PIP-GIRK2 species to mole fractions as described previously [39]. 
  
High-resolution MS spectra were collected using an Exactive Plus with extended mass 
range (EMR) from Thermo Scientific. Samples were analyzed using both the original instrument 
and a modified reverse entry ion source (REIS) coupled to the HCD cell of the Orbitrap [96]. 
Gold-coated capillaries described above were loaded with sample. Operating conditions of the 
REIS were described in detail previously; briefly, ions are generated by nano-ESI, focused with a 
RF ion funnel, and transferred to the HCD cell by an octupole ion guide. All mass spectra were 
collected with 10 µscans at 17 500 mass resolution with an ion injection time of 200 ms. 
Collision energies of 20 eV in-source CID and 70 HCD collision energy for normal operating 
conditions and 110 HCD collision energy for REIS. These energies were chosen to effectively 
desolvate and strip detergents while minimizing perturbations to protein-lipid and subunit 
interactions. MS data from the Exactive Plus EMR is analyzed and mass-species assigned using 
UniDec [95].  
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Results and Discussion 
  
GIRK2 Sample Optimization for Native Mass Spectrometry 
We initially performed protein expression and purification for GIRK2 following 
established methods used for crystallographic studies of GIRK2 [77, 78], and recorded a mass 
spectrum of GIRK2 solubilized in dodecylmaltoside (DDM) detergent micelles. High-energy 
instrument settings were necessary to obtain an interpretable mass spectrum on a Waters Synapt 
G1 instrument (Fig 7A and Fig 8A). The mass spectral peak group with the highest signal 
intensity correspond to the tetrameric channel (~8000 m/z for Fig 7, ~6000 m/z for Fig 8A,B). 
Significant adducts remain bound, even under this high-energy regime, corresponding to a host 
of small molecules contaminants, which we suspect are co-purified lipids. We then used a 
detergent screening approach [9] to identify conditions that remove the co-purified contaminants 
from the complex (Fig 7). From this exhaustive screen of detergents performed at different steps 
in the purification process, including mixtures of detergents, no conditions were found to 
effectively remove all of the bound contaminants while maintaining protein solubility. We then 
explored lipids with detergent-like properties and found the short-chain phospholipid DHPC 
(1,2-diheptanoyl-sn-glycero-3-phosphocholine) to be the most effective at removing adducts 
while minimizing protein aggregation. The mass spectrum of GIRK2 in DDM after DHPC 
treatment had no lipid adducts even under moderate instrument settings (Fig 8B). Although the 
mass spectrum is resolved, it is difficult to preserve native-like structure using DDM, a non-
charge reducing detergent, as evident by broad arrival time distributions and dissociation of the 
complex (Fig 8B and 9A). Similar observations have been made for other membrane proteins 
[22, 27]. Therefore, we exchanged GIRK2 into buffer containing the charge-reducing detergent 
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C10E5 (decylpentaglycol) (Fig 7C). The mass spectrum of this sample is well-resolved and the 
ion mobility (IM) measurements, which report on the rotationally averaged collision cross-
section, indicate compact, native-like arrival times for half of the charge states under the 
optimized instrument settings (Fig 7C and 9B). The measured mass agrees highly with the 
calculated mass (Table 1). The C10E5 detergent micelle requires more energy to release from the 
protein than the commonly used C8E4 detergent, providing an explanation for the partial 
activation of the higher charge states seen in Fig 9B [22]. Notably, the sample following 
established methods in DDM under the same instrument conditions used for the optimized 
sample in C10E5 was largely a hump with some poorly resolved mass spectral peaks observed 
(Fig 10A). Moreover, the C10E5 detergent reduces enough charge such that no dissociation of the 
complex is observed even at the highest energy regime (Fig 10B), which is in accord with other 
charge-reduced membrane protein studies performed previously [22, 27, 97]. 
 
We also acquired data on a higher mass resolution Orbitrap mass spectrometer [46] 
equipped with a custom reverse-entry ion source (REIS-Orbitrap) [98, 99] that yielded sharp 
mass spectral peaks with addition of mass as small as 80 ± 17 Da resolved (Fig 8D). As the 80 
Da addition in mass could be a covalent modification, we prepared a denatured sample of GIRK2 
following a method recently reported by Campuzano and co-workers [100]. The mass spectrum 
of the denatured sample recorded on the Orbitrap mass spectrometer revealed a predominant 
denatured mass of 38,939.65 Da (Fig 11), which is within 2.20 Da of the calculated mass of 
GIRK2 with the initiating methionine removed. Removal of the first residue by methionine 
aminopeptidase is not an uncommon post-translational modification [101, 102]. Moreover, a 
denatured mass consistent with one phosphorylation of GIRK2 was also measured and accounts 
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for a small fraction of the total signal. This percentage of phosphorylation is consistent with the 
decrease in intensity of one and multiple phosphorylation events within the tetrameric complex. 
We then performed a tryptic peptide analysis to confirm phosphorylation and identify site(s) of 
the covalent modification. We obtained a sequence coverage of 52% and a number of peptides 
having only a single phosphorylation were identified (Fig 12A). Of those, four phosphorylated 
residues mapped to surface exposed regions of the cytoplasmic domain near the C-terminus (Fig 
12B). Two serine residues that are part of the linker region between GIRK2 and the TEV 
protease cleavage site of the expression construct were unexpectedly both found to be singly 
phosphorylated. 
 
GIRK2 Interactions With the Peptide Antagonist TPNQ and the Drug Imvermectin  
Given the high-quality samples of GIRK2 revealed by MS above, we next explored if we 
could resolve binding of small molecules, such as toxins and drugs. The first molecule we 
considered was tertiapin, a 21 amino acid peptide isolated from honey bee venom and a potent 
inhibitor of GIRK2 and other IRKs [73]. We used the oxidation resistant form of tertiapin where 
Met13 has been mutated to Q (TPNQ) with a molecular weight of 2452 Da [103]. The mass 
spectrum of a mixture of TPNQ to GIRK2 at a 6:1 molar ratio in the detergent C10E5 revealed 
direct binding of one TPNQ molecule (Fig 13A). Interestingly, the arrival time distributions 
differed significantly for apo and TPNQ bound GIRK2 (Fig 13B). For example, the 17+ charge 
state had a more compact conformer for GIRK2TPNQ whereas the apo species was 
predominantly an extended, activated conformer of the protein (Fig 13B). These results 
prompted us to perform a collision induced unfolding (CIU) experiment where gas-phase 
unfolding is monitored by ion mobility, an approach that has been successfully employed for 
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soluble [32] and membrane protein complexes [104]. The ion mobility profiles begin with a 
native-like arrival time distribution where the applied instrument energy regimes are sufficient to 
remove detergent micelles but insufficient to perturb protein structure (Fig 13C and Fig 14), in 
similar ways to other membrane protein complexes was studied [27]. As collision energy is 
increased, the arrival time distribution transitions to a partially unfolded state (Fig 13C and Fig 
14) at 145 electron volts (eV) for the 17+ charge state of GIRK2. Since charge-reducing 
detergents are used, there is no dissociation of GIRK2 and GIRK2TPNQ complexes even at the 
highest collision energies. Applying algorithms to quantify transitions in CIU profiles [27, 35] 
we calculated an average stabilization for the binding of TPNQ to GIRK2 of 640 and 637 eV for 
the 17+ and 18+ charge states, respectively (Fig 13D). In summary, CIU experiments reveal that 
TPNQ bound GIRK2 significantly stabilizes the channel with an increased resistance to the gas-
phase unfolding forces.  
 
The second small molecule we studied was ivermectin, a hydrophobic drug molecule 
identified in functional assays to activate GIRK2 channels [76, 105]. The drug has a molecular 
weight of 875 Da that is comparable to the mass of PIPs (Fig 15A). Unlike TPNQ, we observed 
no binding of ivermectin to the channel under our experimental conditions even at concentrations 
as high as 300 μM (Fig 15B), which is three-fold higher than values used in previous studies. 
Since functional studies report a PI(4,5)P2-dependent but Gβγ-independent activation of GIRK2 
channels by ivermectin, we incubated GIRK2 with a mixture of ivermectin and a PI(4,5)P2 with 
18:0-20:4 tails (PI(4,5)P2-sa) at 1:100:6 molar ratio, respectively. The mass spectrum for these 
mixtures compared to the mass spectrum to a sample free of ivermectin was indistinguishable, 
implying no direct binding of the drug (Fig 15C, D). Additionally, no significant mass spectral 
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peak broadening or shift was observed in the presence of the drug. These results demonstrate the 
ability of our mass spectrometry approach to identify molecules that are direct binders. 
 
GIRK2 Binding with Phospholipids 
To probe the selectivity of PIPs we incubated GIRK2 with a six-fold molar excess of 
phosphatidylinositol-4-phosphate (PI(4)P), phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2), 
PI(4,5)P2 with dioleoyl acyl chains (18:1-18:1, do), dioctanoyl (8:0-8:0, d8) PI(4,5)P2, 1-
stearoyl-2-arachidonoyl (18:0-20:4, sa) PI(4,5)P2-sa, and phosphatidylinositol-3,4,5-triphosphate 
(PI(3,4,5)P3-sa) (see Table 2 for abbreviations). Native mass spectra for GIRK2 incubated with 
PIPs revealed binding of up to four molecules including peaks corresponding to the apo channel 
(Fig 16). As the mass spectral peaks were broad, we introduced the sample into the REIS-
Orbitrap and obtained higher resolution mass spectra with slightly less lipid-bound fractional 
abundances (Fig 16B). We observed peak splitting in the presence of PI(4,5)P2-d8 corresponding 
to 90 ± 40 Da. After deconvoluting the mass spectra [95] and extracting mole fraction data, 
PI(4,5)P2-do and PI(3,4)P2-do bound with similar abundance to PI(4,5)P2-d8 (Fig 14C). In the 
case of PI(4)P-do, which contains one less phosphate group, the overall abundance of bound 
lipid was significantly reduced as evident by an increase in the fractional abundance of apo 
GIRK2. PI(3,4,5)P3-sa, a lipid with three phosphates groups on the inositol head group, also 
showed a reduction in binding as indicated by a higher fractional abundance of the apo channel 
compared to PI(4)P-do. The mass spectrum for PI(4,5)P2-sa, a lipid with similar acyl chains as 
PI(3,4,5)P3-sa, had comparable binding to the other acyl variants of PI(4,5)P2 studied. These data 
indicate GIRK2 selectively binds PI(3,4)P2 and PI(4,5)P2 with roughly equivalent affinity while 
displaying a lack of sensitivity toward acyl chain length.  
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We next examined the data to compare the gas-phase stabilization imparted by lipids and 
TPNQ. The ATD for PIP1-4 bound to GIRK2 acquired under optimized instrument settings did 
not preserve the native-like distribution for the 17+/18+ ions when compared to GIRK2 bound to 
TPNQ (Fig 17A, B). We then performed CIU on the apo and PI(4,5)P2-do bound to GIRK2 and 
found that a modest stabilization, between 150 and 200 eV, was achieved when four PI(4,5)P2-do 
were bound to GIRK2 (Fig 17E). PIP binding clearly stabilizes the channel but to a lesser extent 
than TPNQ. 
 
To compare the affinity of PIPs to other phospholipids we considered binding of 
phosphatidylinositol (PI) with do-type acyl chains (DOPI), phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) with 1-palmitoyl-2-oleoyl (16:0–18:1, PO) acyl chains at the 
same molar ratio used for the PIP binding studies described above (Fig 16C). In the case of 
DOPI, a precursor for PIPs, there was a significant reduction in binding and only up to three lipid 
binding events were observed compared to four PIPs bound. For POPE, a maximum of two 
lipids were bound, with 66% of the signal corresponding to apo GIRK2. POPC differs from 
POPE by three additional methyl groups on the choline headgroup and was the weakest binder of 
the lipids studied. Other studies have reported the sensitivity of Kir2 to PI(4,5)P2 can be 
modulated by anionic lipids [71], we explored this possibility with GIRK2 and incubated the 
channel with four molar equivalents of PI(4,5)P2-do and POPG (Fig 18). The mass spectrum 
revealed no significant differences in binding of PI(4,5)P2-do compared to samples lacking 
POPG, which would be expected for competitive binding or positive allosteric modulation [91]. 
Taken together, GIRK2 binds PIPs with much higher affinity compared to other phospholipids.  
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GIRK2 Mutant Binding Phospholipids 
The GIRK2R201A mutant, a channel with a slightly shifted cytoplasmic domain rotation 
compared to the wild type, is reported to gate by PIPs independently of Gβγ (Fig 19). Similar 
lipid binding experiments done for the wild type channel was performed for this mutant (Fig 20). 
The most abundant binding was observed for PI(4,5)P2-d8 and binding was similar for PI(4,5)P2-
do, and PI(4,5)P2-sa (Fig 20C). In the case of PI(3,4)P2-do, a significant reduction in binding 
affinity was observed relative to wild-type GIRK2. The mass spectrum for PI(4,5)P2 and 
PI(3,4,5)P3 revealed comparable binding affinity to the wild-type protein. The mutant channel 
also displayed an overall increase in binding affinity towards DOPI, POPC and POPE compared 
to wild-type GIRK2. Taken together, GIRK2R201A displays a greater selectivity towards PIP 
isoforms with head group phosphorylation at the 4 and 5 positions and reduced affinity towards 
the other PIPs. 
 
In a similar fashion to the wild-type channel, we examined the GIRK and GIRKR201A data 
to compare the gas-phase stabilization imparted by lipids and TPNQ. GIRKR201A bound to TPNQ 
was significantly stabilized to a level that was comparable to the wild-type protein (Fig 21, Fig 
22). Like the wild-type protein, PIPs had similar stabilization to the mutant channel under the 
optimized instrument settings used. Interestingly, when we incubated GIRK2, TPNQ and 
PIP(4,5)P2-d8 at a molar ratio of 1:6:6, respectively, all 17+ species with TPNQ bound show a 
large degree of stabilization with faster, more compact arrival times (Fig 23). Lastly, we 
compared charge states that represent partially unfolded and native-like states (the 21+ and 16+, 
respectively) (Fig 24). Significant dissociation was observed for DOPI, POPC, and POPE at 
higher charge states (Fig 24B-C). In contrast, the abundance of PIPs bound were nearly identical 
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between the two charge states suggesting that GIRK2 specifically bind PIPs. This phenomenon is 
supported by observation of increased binding affinity for PIPs in relation to other phospholipid 
species. 
 
Discussion of Results 
In order for a drug to be efficacious it must directly bind and modulate the function of the 
target protein [106, 107]. Here, we demonstrate the utility of native mass spectrometry to 
monitor direct binding of small molecules to GIRK2. The high-quality samples produced was 
instrumental in enabling the first high-resolution native mass measurements of a eukaryotic ion 
channel with the striking ability to resolve adducts as small as 80 Da on the intact 156 kDa 
tetrameric complex. These adducts were further confirmed using traditional top-down and 
bottom-up proteomic approaches to be phosphorylation of GIRK2 on residues previously 
unreported. The covalent modifications mapped to surface exposed residues located in the CTD 
and, unexpectedly, to both serine residues within the linker region of the expression construct. 
Removal of the serine residues in the linker region will undoubtedly improve protein 
homogeneity. For GIRK2, the reported phosphorylation events that have roles in protein 
trafficking and modulating activity are located in the N-terminal region [54, 108-110]. Although 
the new GIRK2 phosphorylation sites we identified here warrant further study, it is important to 
highlight that a native mass spectrum can provide insight in protein modifications that may go 
undetected. The methods in optimizing the sample quality to enable these measurements are 
numerous and summarized to highlight key points (Fig 25). Taken together, our mass 
spectrometry results and methods provide the foundation for future studies to not only improve 
sample quality but also detect post-translational modifications. 
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The optimized instrument settings for GIRK2 resulted in a balance of compact, native-
like arrival times for half of the charge states as determined by IM. Here, we have avoided 
interpreting activated ions and only deconvoluted regions of the mass spectrum corresponding to 
ions with native-like arrival times. One potential issue this technique often faces is with regard to 
whether the electrostatic and hydrophobic interactions of the complex can be purturbed in the 
gas-phase. However, in our previous reports [39, 88] and from the Klassen group [89], binding 
thermodynamics for soluble protein-ligand, membrane protein-protein, and membrane protein-
lipid interactions determined by native MS are in direct agreement with surface plasmon 
resonance and isothermal titration calorimetry, which are gold-standards for solution-phase 
measurements. The fact that similar equilibrium constants and thermodynamic parameters to 
solution measurements can be determined by native MS suggest the altered electrostatic and 
hydrophobic interactions in the gas-phase are negligible. Although corroborating our lipid 
binding data with another assay would be a logical follow-up study, our existing ion mobility 
measurements can help us minimize potential gas-phase artifacts due to instrument energy 
activation. We can extract mole fraction lipid binding data from only ions with compact, native-
like arrival times, and interpret the data with confidence. 
 
Native ion mobility mass spectrometry not only can monitor direct binding events but 
probe membrane protein stability in complex with small molecules. The IM-MS data for GIRK 
bound to TPNQ provide compelling evidence that the toxin binds and significantly stabilizes the 
channel. Increased protein stabilization upon ligand binding, including membrane protein-lipid 
interactions, has been well characterized by ion mobility [27, 32]. Notably, the gas-phase 
stabilization observed here for GIRK2•TPNQ is over six-fold more stabilizing compared to 
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values reported for membrane protein lipid interactions for a single binding event [27]. In the 
case of the recently reported GIRK2 activator ivermectin, no direct binding was observed. The 
absence of ivermectin binding to GIRK2 using our native IM-MS approach suggests the drug 
molecule may bind weakly and/or require a lipid bilayer to support binding. Another possibility 
for no apparent binding is the energy regime required to release the protein from the detergent 
micelle is too high and may dissociate the bound drug. 
 
Our direct mass measurements of the GIRK2-lipid complexes reveal that both GIRK2 
and GIRK2R201A display distinct specificity for the phosphorylation pattern of the inositol head 
group. More specifically, GIRK2 and GIRK2R201A both have high affinity for PI(4,5)P2 whereas 
the wild-type channel also has comparable affinity for PI(3,4)P2. Although the majority of assays 
use predominantly PI(4,5)P2 to activate GIRK2, our results are largely in agreement with 
functional studies for other GIRKs, which observed head group selectivity compared to other 
IRKs [68, 71, 79]. The slight differences between our direct binding measurements and channel 
activation represents an interesting question as to the correlation between PIP binding events and 
gating. Moreover, the acyl chain variations among the PIPs explored here show insignificant 
differences in preference that is in contrast with functional studies that reported differences in 
acyl chains lengths for GIRK1/4 [68]. Although GIRK2 is in the same subfamily as GIRK1/4, 
the data suggests these two channels have a different selectivity towards the lipid tails of PIPs. In 
summary, GIRK2 lipid selectivity is largely determined by head group phosphorylation pattern 
of the PIPs, and not necessarily through acyl chain length. 
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Mass spectrometry results also reveal that GIRK2 and GIRK2R201A bind PIPs 
cooperatively and with much higher affinity than highly abundant phospholipids in the plasma 
membrane [111]. GIRK2 binds DOPI, POPC, and POPE with reduced binding affinity compared 
PIPs. At equimolar concentrations, up to three lipid binding events to GIRK2 were observed for 
DOPI, POPC, and POPE whereas four PIPs can be seen bound. The much higher binding affinity 
of GIRK2 towards PIPs provides evidence for how these channels can bind PIPs that are found 
in low abundance compared to bulk lipids in the plasma membrane.   
 
Allosteric modulation of protein function by binding of molecules at remote sites is an 
important biological phenomenon [112-114]. Here, GIRK2R201A allowed us to explore lipid 
binding to a channel that induces a rotation in the CTD, similarly to Gβγ-activated state of GIRK2 
[77]. The mutant was primarily used because the biochemical isolation of the GIRK2•Gβγ 
complex in detergent solutions has so far been unsuccessful [78]. Early studies indicate GIRK 
interactions with PI(4,5)P2 are weak and that there is an increase in relative affinity for the Gβγ-
activated channel [61, 115]. However, our data suggest that rotation of the GIRK2 CTD when 
bound to Gβγ, as mimicked here by GIRK2
R201A, does not enhance or decrease the binding 
affinity towards PI(4,5)P2. Rather, rotation of the CTD allosterically modulates remote PIP 
binding sites, tuning the channel by reducing the binding affinity for PIP isoforms known to 
weakly or not activate GIRKs. Our findings are in-line with recent MS studies suggesting 
membrane protein-lipid interactions can allosterically modulate interactions with regulatory and 
signaling proteins [88, 116]. Although the R201A CTD rotation is greater than the GIRK2•Gβγ 
complex, it is reasonable to suggest that rotation of the CTD allosterically tunes the selectivity of 
the channel towards PIPs.  
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 
 Native ion-mobility mass spectrometry (IM-MS) demonstrated individual protein-ligand 
binding details can be quantitatively analyzed. The ammonium channel AmtB was used to help 
establish rigorous methods for IM-MS studies for more complex eukaryotic membrane 
complexes, such as the inward rectifying potassium (IRK) channels from mammals. In this 
dissertation, IM-MS was used to monitor direct binding of lipids and a toxin to a mouse G-
protein-gated IRK (GIRK2). This study revealed direct yet unprecedented details about the 
channel that are conventionally difficult to access, such as how the signaling lipids, 
phosphoinositides (PIPs), may selectively bind GIRK2 with much higher affinity over other 
phospholipids. In addition, using the R201A mutant channel which exhibits a cytoplasmic 
domain (CTD) rotation similar to the G-activated state, it showed that an altered structure can 
allosterically modulate binding selectivity towards PIPs at a distant site. The level of detail from 
mass measurements of an optimized membrane channel has also guided us to observe previously 
unreported phosphorylation events to GIRK2’s C-terminus. Ion mobility measurements, coupled 
to native MS, also provides useful information on the structural consequences of non-covalent 
interactions between a protein and its ligand(s). Going forward, the continued improvement in 
both sample preparation and native MS technology such as IM resolution will allow us to 
decipher further details of disease-related membrane proteins such as GIRK2. Application of 
high-resolution, native IM-MS techniques will provide a new window into the structural and 
biophysical details of complex cellular machinery to greater depth. 
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APPENDIX A 
 
 
 
Figure 1. Representative mass spectra of AmtB bound to 1-palmitoyl-2-oleoyl phosphatidic acid 
(POPA) recorded at different source temperatures and collision voltages. The mass spectrum 
acquired at ambient source temperature (23 °C) produced an unresolved spectrum at the two 
lowest collision voltage settings. Given the configuration of the Synapt G1 instrument [40], these 
results demonstrate the necessity of “in-source” activation prior to entrance into the quadrupole 
such that resolved ions can be isolated. Increasing source temperature activates ions comparably 
to increased collision voltage settings at ambient source temperature.  
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Figure 2. Collision induced unfolding (CIU) profile of the 15+ charge state of AmtB bound to 
two 1-palmitoyl-2-oleoyl phosphatidic acid (POPA). Shown are CIU profiles acquired using 
either (a) IM-MS or (b) MS-IM-MS with source temperature set to 40, 80 or 120 ºC. CIU 
profiles were generated using the software program, Pulsar [35]. Representative mass spectrum 
recorded at a collision voltage of 20 V is shown with their respective CIU profiles recorded at 
different source temperatures. The first transition from a native-like to a partially unfolding 
intermediate, calculated by Pulsar, is shown as a dashed line. The faint overlay of MS-IM-MS 
CIU profile in the IM-MS CIU profile (a, left panel) is indicated by red arrows.  
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Figure 3. MS and MS-IM-MS of AmtB in complex with 1-palmitoyl-2-oleoyl 
phosphotidylglycerol (POPG) recorded at different collision voltages and source temperature of 
120 oC. (a) Representative mass spectrum of AmtB bound to POPG under native-like conditions. 
(b) Isolation of the 15+ charge state of AmtB(POPG)2 prior to activation in the trap (bottom 
panel). Upon activation in the trap, bound POPG molecules are ejected as a neutral species with 
increasing trap collision voltage.   
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Figure 4. MS-IM-MS CIU profiles of AmtB bound to (a) two or (b) one POPG molecule(s). MS-
IM-MS data recorded at a source temperature of 120 oC. The CIU profile for the product AmtB 
species minus an ejected lipid is shown on the right. The first transition lines are shown as 
described in Figure 2.  
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Figure 5. Mole fraction of AmtB lipid species across CIU profiles for (a) IM-MS and MS-IM-
MS of AmtB bound to (b) one and (c) two lipid(s). Data was recorded at a source temperature of 
120 °C. Dashed lines indicate the estimated collision voltage at which half of the bound lipid has 
been ejected. Phosphatidylserine (POPS), phosphatidylethanolamine (POPE), and tetra oleoyl 
(18:1) cardiolipin (TOCDL). Reported are average and standard deviation (n=3). 
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Figure 6. Stabilization of AmtB bound to lipid determined from IM-MS and MS-IM-MS. The 
head group structure of each lipid is shown. Stabilization was calculated by comparing the 
transitions in CIU profiles for apo and lipid-bound states in units of electron volts using 
calculation methods described literature [27, 35].  Reported are the average and standard 
deviation (n=3). 
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Figure 7. Representative mass spectra of the GIRK2-GFP fusion protein showing the result of detergent 
screening performed to optimize sample quality for the GIRK2-GFP fusion protein. (A), Initial 
preparation of GIRK2 extracted in 3% DDM and analyzed in MS buffer containing 0.05% DDM, in a 
similar fashion to the established protocol for structural studies [78] but without performing size-
exclusion chromatography (SEC). The mass of the tetrameric complex cannot be ascertained due to 
heterogeneous adduct species causing the significant peak broadening. Some contaminant proteins that 
were co-purified were visible on the left side of the spectrum. (B) GIRK2-GFP purified in 4% NG (n-
Nonyl-β-d-glucoside, Anatrace), followed by SEC and MS analysis in buffers containing 0.05% DDM. 
While still difficult to accurately determine, the mass of the complex is much closer to the calculated 
average as bound adducts were reduced significantly. (C) GIRK2-GFP purified in 4% DDM, followed by 
buffer A wash supplemented with 2% NG, then analyzed in MS buffer containing 0.05% DDM. The 
combinatorial effect of both DDM and NG washes allowed sufficient removal of adducts such that the 
apo-GIRK2-GFP fusion protein is revealed at roughly 276.2 kDa.   
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Figure 8. Optimization of mouse GIRK2 for native mass spectrometry studies. (A) Initial 
preparation of GIRK2 in dodecylmaltoside (DDM) following established protocols for structural 
studies [77]. The mass spectrum was recorded using maximum energy settings to reveal 1,350 
Da adducts bound to GIRK2. (B) Mass spectrum of GIRK2 in DDM after DHPC treatment, 
which reveals a well resolved mass spectrum with the lipid adducts removed. DHPC treated 
GIRK2 in the charge-reducing detergent, C10E5 acquired under minimal energy regimes on a (C) 
Waters Synapt G1 and (D) Thermo Exactive plus EMR modified with a rear-entry source [98]. 
The mass spectra resolves small molecule adducts bound to the tetrameric complex. 
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Figure 9. Representative ion mobility mass spectra of GIRK2 tetramer (~156.2 kDa). GIRK2 in 
MS buffer containing 2x critical micelle concentration (CMC) of (A) DDM or (B) C10E5. The 
average charge state of GIRK2 in DDM buffer is about 26+ whereas in C10E5 the average is 
reduced to about 18+. Charge reduction afforded additional stability for the GIRK2 complex in 
the gas-phase, where more than half of the charge states’ arrival-times fall on a trend-line that is 
typically associated with “native-like” protein complexes.  
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Figure 10. Optimization of sample purification is required to obtain a resolved native mass 
spectrum. A) Native mass spectrum of GIRK2 purified following previously established methods 
[77] in DDM collected at the same instrument conditions as in Fig 7C yields a hump with a 
unresolved mass spectrum. B) Optimized sample in C10E5 after a DHPC treatment as described in 
methods. The activation energies were 120 V and 80 V for the trap and transfer cell, 
respectively. No dissociated monomers or stripped oligomers are observed under these 
experimental conditions for GIRK2 liberated from C10E5. 
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Figure 11. Mass spectrum of intact and denatured GIRK2. Inset shows zero-charge mass 
spectrum with labeled mass species. The table shows the summary of the mass species. 
*Monomer mass was calculated with the initiating methionine removed. Roughly 19% of signal 
intensity is attributed to the phosphorylated species.   
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Figure 12. Bottom-up MS analysis of GIRK2 tryptic peptides. A) Sequence coverage (53%) is 
shown in green and identified phosphorylation sites labeled with an orange circle. Non GIRK2 
residues from the expression construct are shown in grey colored font. B) Structural of GIRK2 
(PDB 3SYA) with identified phosphorylation sites shown as yellow spheres.  
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Figure 13. Mass spectrometry captures honey bee toxin, Tertiapin Q (TPNQ) binding and 
stabilization of GIRK2. (A) Mixture of GIRK2 and six molar equivalents of TPNQ in C10E5. One 
TPNQ binding event is observed in the mass spectrum. (B) Ion mobility mass spectrum indicates 
the 17+ charge state stabilizes the native-like state of the channel when bound to TPNQ. (C) 
Collision induced unfolding (CIU) plots for the 17+ charge state (left) apo and (right) TPNQ 
bound GIRK2. (D) Stabilization calculated from parameters defined by fitting GIRK2 (17+ and 
18+) bound to TPNQ using the software program, PULSAR [27, 35] Reported are average and 
standard deviation from repeated measurements (n = 3) in kiloelectron volts (keV). 
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Figure 14. CIU unfolding profiles for 17+ and 18+ charge states of apo and TPNQ bound GIRK2. 
The blue plots represent experimental data and orange plots are fits to the experimental data 
using the software program, PULSAR [35]. Reported in the fitted models is the chi-square fitting 
statistic from PULSAR. TPNQ binding to GIRK2 significantly stabilizes the channel as evident 
by large shift in the transition from native-like to a partially unfolded state. 
  
 71 
 
 
 
  
Figure 15. Native mass spectra of GIRK2 doped with ivermectin and/or PI(4,5)P. (A) 
Representative mass spectrum of GIRK2 showing the 17+ and 18+ charge states. Blue lines show 
the estimated resolution achieved on the GIRK2 complex, and orange lines show hypothetical 
ivermectin binding events at the same resolving power. (B) Representative mass spectrum 
showing 17+ and 18+ charge state for GIRK2 in the presence of 300 μM ivermectin which is 
solubilized in MS buffer containing 5% ethanol and 3% DMSO. No binding of ivermectin was 
observed at the calculated m/z values for either wild-type or GIRK2R201A (data not shown for 
GIRK2R201A or concentrations below 300 μM) (C) Mass spectrum of mixture containing 500 nM 
GIRK2 and 3 μM PI(4,5)P2-sa, the most abundance form of PI(4,5)P2 in mammalian cells [81]. 
(D) Native mass spectrum for a mixture of 500 nM GIRK2, 3μM PI(4,5)P2-sa and 50 μM 
ivermectin. No changes to the lipid binding pattern is observed in the presence of ivermectin, but 
there is a shift in the overall charge-state distribution.  
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Figure 16. Selective binding of PIPs and phospholipids to GIRK2. Representative mass spectra 
of a mixture of 0.5 µM GIRK2 and 3 µM PI(4,5)P2-d8 acquired on the (A) Synapt G1 and (B) 
Exactive Plus EMR. Up to four lipid binding events are observed in the mass spectra, and higher 
resolution achieved by the EMR enabling small molecule adducts to be resolved. (C) Plot of 
mole fraction data obtained from deconvoluting mass spectra for various lipids mixed with 
GIRK2 at a molar ratio of 6:1, respectively. GIRK2 has much higher affinity for PIPs over other 
phospholipids. Reported is the average and s.e.m. (n = 3). Student’s t-test (two-tailed) was used 
for statistical analysis (**P<0.01) with the apo molar fraction being used for comparison. Lipid 
abbreviations are provided in Table S2.  
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Figure 17. Collision inducing unfolding plots for apo and PIP2 bound GIRK2. (A) and (B) shows 
the mass and ion-mobility spectrum for GIRK2 bound to PI(4,5)P2-do, respectively. (C) and (D) 
shows the CIU profiles and the fitted model for unfolding of apo GIRK2 and GIRK2 bound to 
four PI(4,5)P2-do molecules, respectively. (E) Stabilization calculated from parameters defined 
by fitting GIRK 17+ and 18+ bound to four PI(4,5)P2-do molecules. Reported are average and 
standard deviation from repeated measurements (n=3) in electron volts (eV). 
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Figure 18. Deconvolution of high-resolution native mass spectra of GIRK2 bound to different 
lipids. (A)  GIRK2 incubated with four molar equivalents of PI(4,5)P2-do. (B) GIRK2 incubated 
with a equimolar mixture of POPG and PI(4,5)P2-do. For the mixture, no change in binding of 
PI(4,5)P2-do is observed that would indicate competition or positive allosteric modulation. 
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Figure 19. Stuctures of wild-type GIRK2 (PDB 3SYA), R201A (3SYQ) and comparison 
between the cytoplasmic domain (CTD) rotation as a result of the mutation. Center bottom 
shows the Gβγ bound form of wild-type GIRK2 (PDB 4KFM). The rotation of the GIRK2 
R201A’s CTD mimics the structure of the “open” form of the WT as a result of Gβγ binding.  
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Figure 20. Mass spectrometry reveals a change in the selectivity of GIRKR201A, a channel with 
CTD rotation that has been proposed to mimic the Gβγ-activated state, towards PIPs and 
phospholipids. Representative mass spectra of GIRK2R201A mixed with six equivalents of (A) 
PI(4,5)P2-do and (B) PI(4,5)P2-sa. (C) Mole fraction derived from mass spectrometry data for 
GIRK2 mixed with different lipids at six-fold molar excess. Reported is the average and s.e.m. (n 
= 3). Student’s t-test (two-tailed) was used for statistical analysis (*P<0.03) as described in Fig 
16. 
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Figure 21. GIRK2R201A mixed with TPNQ reveals the bound toxin significantly stabilizes the 
channel. (A) Native mass spectrum of GIRK2 mixed with 5 μM TPNQ. (B) Ion mobility mass 
spectrum showing the arrival times for 16+, 17+ and 18+ charge states. (C) CIU profiles for the 
17+ charge state apo and TPNQ bound GIRK2R201A, orange dotted line indicates the calculated 
transition voltage from PULSAR [35]. (D) Stabilization calculated from parameters defined by 
fitting GIRK2 (17+ and 18+) bound to TPNQ. Reported are average and standard deviation from 
repeated measurements (n=3) in electron volts (eV). Stabilization of the mutant channel by 
TPNQ is statistically similar to wild-type channel. 
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Figure 22. CIU unfolding profiles for both 17+ and 18+ charge states of apo and TPNQ bound 
GIRK2R201A. Shown as described in Figure 14. 
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Figure 23. Representative mass and ion mobility spectrum of GIRK2 in the presence of both 
TPNQ and PI(4,5)P2-d8. (A) Mass spectra of the complex showing mass species for the GIRK2 
complex and its various ligand-bound arrangements. Note that the signal for three-lipid bound 
GIRK2 overlaps with the TPNQ-bound GIRK2, and four-lipid bound GIRK2 overlaps with the 
TPNQ-bound GIRK2 with one lipid also bound. (B) Ion mobility spectrum of the same species. 
The 17+ charge state species with TPNQ bound clearly demonstrates stabilized gas-phase arrival 
times. Resolution of all combinations is possible with mass spectrometry instruments with higher 
resolution.  
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Figure 24. Comparison between partially activating (21+) and native-like (16+) charge states for 
different lipids bound to GIRK2. (A) Enlargement of regions of mass spectra for 21+ and 16+ 
charge states of GIRK2 and GIRK2R201A bound to different lipids. For all PIPs, the fractional 
abundances of apo and lipid-bound GIRK2 are very similar between the two charge states. 
However, the other lipids (PI, PC and PE) display a dramatic reduction in the amount of lipid 
retained at the higher charge state. Calculated differences between the mole fraction of lipids 
bound to the 16+ compared to the 21+ charge state of (B) wild-type and (C) R201A mutant 
GIRK2. 
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Figure 25. A generalized overview of the workflow of GIRK2 optimization for native MS 
studies. We performed screening of expression constructs, growth conditions, lysate 
treatment, purification conditions, detergent screens all as a part of the effort in obtaining 
better quality sample suitable for native mass spectrometry. The end goal is the 
unambiguous resolution of individual small molecules – all under 1,000 Da – bound to 
the intact 156,000 Da channel. 
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APPENDIX B 
 
Table 1. Calculated and measured masses for GIRK2R201A and GIRK2 bound to different ligands acquired 
on a Synapt G1 instrument. Measured mass was determined by deconvolution of native mass spectra 
using the program, UniDec.[95] For ligands bound to GIRK2, the addition of mass to the apo GIRK2 
mass is reported. The reported standard deviation was calculated directly from the width of the zero-
charge mass spectrum from UniDec after deconvolution. 
Species Calculated Mass (Da) Measured Mass (Da) 
GIRK2 156,292 156,296 ± 230 
GIRK2 bound to:   
Tertiapin Q ∆2,452 ∆2,450 ± 231 
Ivermectin ∆875 –    
PI(4,5)P2-d8 ∆798 ∆740 ± 320 
PI(4,5)P2-do ∆1,074 ∆1,080 ± 351 
PI(3,4)P2-do ∆1,074 ∆1,060 ± 353 
PI(4)P2-do ∆977 ∆922 ± 372 
DOPI ∆880 ∆920 ± 361 
PI(3,4,5)P3-sa ∆1,195 ∆1,060 ± 379 
PI(4,5)P2-sa ∆1,098 ∆1,020 ± 375 
POPC ∆760 ∆802 ± 281 
POPE ∆718 ∆701 ± 357 
GIRK2R201A 155,952 155,989 ± 193 
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Table 2. Full name and abbreviations for lipids used in this study.  
Lipid Abbreviation Acyl Chains 
1,2-dioctanoyl-phosphatidylinositol-4',5'-bisphosphate PI(4,5)P2-d8 08:0-08:0 
1,2-dioleoyl-phosphatidylinositol-4',5'-bisphosphate PI(4,5)P2-do 18:1-18:1 
1,2-dioleoyl-phosphatidylinositol-3',4'-bisphosphate PI(3,4)P2-do 18:1-18:1 
1,2-dioleoyl-phosphatidylinositol-4'-phosphate PI(4)P2-do 18:1-18:1 
1,2-dioleoyl-phosphatidylinositol DOPI 18:1-18:1 
1-stearoyl-2-arachidonoyl- phosphatidylinositol-3’,4',5'-bisphosphate PI(3,4,5)P3-sa 18:0-20:4 
1-stearoyl-2-arachidonoyl- phosphatidylinositol-4',5'-bisphosphate PI(4,5)P2-sa 18:0-20:4 
1-palmitoyl-2-oleoyl-phosphatidylcholine POPC 16:0-18:1 
1-palmitoyl-2-oleoyl-phosphatidylethanolamine POPE 16:0-18:1 
 
 
 
